M a r c h 2 0 , 2 0 2 6 Announcement of Agreement to Acquire Breathe Right

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Safe Harbor Disclosure 2 This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the timing of the closing of the acquisition; the tax benefits from the acquisition; the Company’s ability to expand the acquired brand portfolio and create growth; the impact of the acquisition on the Company’s revenues, EBITDA, gross margin, EBITDA margin, free cash flow, EPS, Adjusted EPS, organic revenue, and net leverage; and the Company’s ability to rapidly delever. Words such as “anticipate,” “opportunity,” “continue,” “expect,” “enable,” “outlook,” “can,” “will,” “may,” “should,” “could,” “would,” and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company’s expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the ability to meet the closing conditions; the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and supply disruption; the impact of economic, financial market and business conditions; consumer trends; competitive pressures; the impact of the Company’s advertising and promotional and new product development initiatives; customer inventory management initiatives; the ability to pass along rising costs to customers without impacting sales; fluctuating foreign exchange rates; evolving U.S. and international tariffs and trade actions; geopolitical instability; and other risks set forth in Part I, Item 1A. Risk Factors in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise. Non-GAAP and Other Financial Information In addition to financial information reported in accordance with generally accepted accounting principles (GAAP), we reference acquisition EBITDA which is a non-GAAP financial measure and represents earnings before interest, taxes, depreciation and amortization, as adjusted. Management believes the presentation of EBITDA provides useful additional information to investors about scale of operations in relation to Prestige. Net leverage ratio reflects net debt / covenant-defined EBITDA. Other adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule. We have italicized our trademarks and trade names, which are the property of the Company or its subsidiaries, when they appear in this presentation.

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Today’s Agenda 3 I. Strategic Rationale II. Portfolio Overview III. Transaction & Financial Highlights IV. The Road Ahead

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T I. Strategic Rationale

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Highly Compelling Strategic and Financial Rationale 5 Transaction Meets Prestige’s Disciplined Strategic, Execution and Financial Acquisition Criteria ✓ Adds a Leading Global Brand in the Attractive “Better Breathing” Space ✓ Compelling Brand-Building Opportunity Expands Both Category and International Footprint ✓ Well-Aligned with Core Competencies ✓ Accretive Financial Profile and Anticipated Strong Economic Returns ✓ Rapid De-Leveraging Supported by Robust Free Cash Flow Profile

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T II. Portfolio Overview

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Scaled Platform of Leading OTC Consumer Healthcare Brands 7 • Synonymous with Better Breathing Solutions • #1 Nasal Strip with Global Reach • Long-Standing Equity Since the Early 1990s • #1 Most Trusted Children’s Cold Relief Brand by Pharmacists1 (1) Based on 2024 Brandspark / Newsweek Most Trusted by Pharmacists Awards. • #2 Branded Oral Analgesic Loyalty Brands • Diverse Set of Brands Generating Strong Cash Flow to Support Reinvestment Across Portfolio Highly Attractive Financial Profile Revenue Mix ✓ ~$200M Revenue ✓ 70%+ Gross Margin ✓ 45%+ EBITDA Margin ✓ Strong FCF Conversion ~34% ~66% Other Brands

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Tangible Relief: Immediately Increases Nasal Air Flow By Up to ~30% Drug-Free Product: Safe to Use with No Side Effects Proprietary Technology: Enabling Superior Experience Strong Brand Equity: 92% Aided Awareness, 53% Unaided Awareness Broad Consumer Appeal: Enhanced Claims About Product Efficacy Across Use Cases (Sleep Wellness, Snoring, Sport, Allergies, Travel) Engaged Consumer Base: Loyal Users Using 150+ Strips Per Year Highly Loyal Consumer: 89% Consecutive Repeat Rate Significant Upside: ~3% Current Household Penetration Rate Breathe Right®: The Better Breathing Authority 8 Original Extra Strength Lavender Menthol Breathe Right ® Tan – Stays on Better, Longer Original Extra Strength Product Portfolio Breathe Right ® Clear – Better for Sensitive Skin, Easy to Remove

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T An Iconic Global Brand 9 Breathe Right is the Clear Category Leader… (Nasal Strips Market Share) $125M+ Revenue …With International Reach… (Revenue Mix by Geography) … with Compelling Financial Attributes Strong Revenue Outlook Stable Operating Model Breathe Right Will Be the Largest Brand in Prestige’s Portfolio and Represent a New Category for Prestige ~60% Market Share U.S. & Canada International 71% 29%

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T III. Transaction & Financial Highlights

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T • Adds Breathe Right®, the #1 nasal strip brand in the attractive better-breathing category • Aligns with Prestige’s business model and core competencies • ~15% of revenue is international, mostly in Europe, providing long-term growth opportunities • Accretive financial profile supports long-term financial algorithm • Transaction is expected to be financed with cash on hand and a new term loan credit facility • Expected pro-forma bank-defined net leverage of ~4.0x at close, with clear path to return to long-term leverage target in fiscal 2028 • Expect rapid deleveraging and strong free cash flow generation consistent with prior acquisitions • Acquisition is expected to close during the first half fiscal 2027 ending September 30, 2026 • Subject to certain closing conditions, including regulatory approvals • Acquiring a portfolio of OTC brands centered around Breathe Right® from Foundation Consumer Healthcare • Purchase Price of $1.045 billion in cash, or ~$900 million net of anticipated tax benefits • Generated ~$200 million of revenue and ~$95 million of EBITDA over the twelve months ended December 31, 2025 • Purchase Price represents ~11.0x EBITDA, or ~9.5x net of anticipated tax benefits • Transaction is immediately accretive to revenue, margins, earnings per share and free cash flow Transaction Overview Overview Strategic Rationale Financing Timing 11

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Transaction Meaningfully Strengthens Scale and Financial Profile 12 Note: Dollar values in millions. (1) LTM as of 12/31/2025. Enhances Prestige Revenue1 Scale … ~$1,100 ~$1,300 Standalone Pro Forma Transaction is Attractive and Reinforces Prestige’s Long-Term Algorithm ~ +1.2x … with Strong Profitability1 Top 5 Brands by Revenue (Pro-Forma) ~35% $0.25+ Estimated Pro-Forma1 Company EBITDA Margin Estimated Annualized EPS Accretion

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T 4.1x 3.8x 3.3x 2.8x 2.4x 2.4x ~4.0x <3.0x Q2 FY22 FY 22 FY 23 FY 24 FY 25 FY 26E Q2 FY27E FY 28E Industry-Leading Free Cash Flow Supports Rapid De-Leveraging Transaction Financing Cash Generation • Transaction is expected to be financed with cash on hand and a new term loan credit facility • Anticipated pro-forma bank-defined net leverage of approximately 4.0x at close • Expect rapid deleveraging consistent with prior acquisitions given strong free cash flow generation • Clear path to return to the Company’s long-term leverage target (<3.0x net leverage) in fiscal 2028 Prestige Bank-Defined Net Leverage Ratio Over Time 13

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T IV. The Road Ahead

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Proven Strategy Delivers Long-Term Performance Proven Ability to Execute Value Creation Strategy 1 Investing for Growth with Proven Brand-Building Playbook 2 Superior Business Attributes Drive Strong Free Cash Flow 3 Scalable & Efficient Platform Enables Capital Allocation Optionality +3.4% +2.4% +8.8% Revenue Organic Revenue1 Adj. EPS2 (1) Reflects GAAP Total Revenues excluding the impact of foreign currency exchange rates. (2) Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding. 15 Prestige 5 Year CAGR’s FY 2020 to FY 2025

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Repeatable and Consistently Disciplined Approach to M&A Portfolio Expansion Added Business, Geographic Capabilities Key Brands Select M&A Examples 2012 2013-14 2014 2015 2016 2021 2025 2026 11+ Acquisitions in Past 16 Years 16

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Portfolio & Strategy Well-Positioned for Long-Term Value Creation 1 Diversified Portfolio of Leading, Trusted Brands 2 Established Organic Growth Brand-Building Playbook 3 Superior Financial Profile Generating Consistent Free Cash Flow 4 Scalable Platform 5 Organic Growth Reinforced by Proven & Repeatable M&A Strategy Prestige’s Business Attributes & Execution Drive Superior Shareholder Value Creation 17

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T Q&A

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T 19 Reconciliation Schedules Organic Revenue, Adjusted Net Income & Adjusted EPS a) Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition. Items related to divestiture represent costs related to divesting of assets sold. b) Income tax effect of above adjustments using the normalized tax rate. c) Income tax adjustment to adjust for discrete income tax items. Note: Amounts may not add due to rounding Year Ended March 31, 2025 2020 Net Income Adjusted EPS Net Income Adjusted EPS (In Thousands, except per share data) GAAP Net Income (Loss) and Diluted EPS $ 214,605 $ 4.29 $ 142,281 $ 2.78 Adjustments: Transition & other costs associated with new warehouse and divestiture in Cost of Goods Sold(a) 9,170 0.18 Loss on disposal of assets 382 0.01 Loss on extinguishment of debt 2,155 0.04 Tradename impairment 12,466 0.25 - - Tax impact of adjustments(b) (2,961) (0.06) (2,974) (0.06) Normalized tax rate adjustment(c) 2,236 0.04 318 0.01 Total Adjustments 11,741 0.23 9,051 0.18 Non-GAAP Adjusted Net Income and Adjusted EPS $ 226,346 $ 4.52 $ 151,332 $ 2.96 Year Ended March 31, 2025 2020 (In Millions) GAAP Total Revenues $ 1,137.8 $ 963.0 Revenue Change CAGR 3.4% Adjustments: Impact of foreign currency exchange rates (0.1%) Impact of acquisitions & divestitures(a) (0.9%) Total Adjustments (1.0%) Non-GAAP Organic Revenue CAGR 2.4% a) Removes the effects of our Akorn acquisition and strategic exit of certain private label business

M A R C H 2 0 2 6 A C Q U I S I T I O N A N N O U N C E M E N T